What does HepaRegeniX GmbH do?
HepaRegeniX GmbH is a clinical-stage company developing novel therapies to treat acute and chronic liver diseases. The company is focused on harnessing innovative small molecules that stimulate liver regeneration, notably through its lead candidate HRX-215 and a pipeline that includes HRX-233 for targeting treatment-resistant tumors.
How much did they raise?
The company raised €21.5m in funding with Wellington Partners leading the round, complemented by participants such as Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, and Ascenion GmbH.
What are their plans for the money?
HepaRegeniX plans to deploy the funds to complete its ongoing Phase Ib trial and advance a Phase IIa clinical trial for HRX-215, aiming to prevent post-hepatectomy liver failure, enable the use of smaller living donor liver grafts, and treat severe alcohol-associated hepatitis. This advancement could significantly impact liver disease management and potentially extend therapeutic options to certain cancers.
What have they achieved so far?
The company has already demonstrated the safety profile of HRX-215 in early clinical trials and is building on these promising results to further develop its regenerative therapies.
